1)Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009
2)Akuta N, et al:Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380, 2005
3)Enomoto N, Maekawa S:HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 53:66-69, 2010
4)El-Shamy A, et al:Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:38-47, 2008
5)Akuta N, et al:Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429, 2010
6)Hayashi N, et al:Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan;CONCERTO-1, a phase III trial. J Hepatol 61:219-227, 2014
7)Izumi N, et al:Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan;The CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 49:941-953, 2014
8)Kumada H, et al:Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59:2083-2091, 2014